Evidence map›Paper›PMID 27591914›Full record

ArticleThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2016

Clinicians' Views on Treatment-Resistant Depression: 2016 Survey Reports.

Katarina Arandjelovic, Harris A Eyre, Helen Lavretsky

Registry-linked trialAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03473431 (A Pilot Study of a Single Infusion of Ketamine in Relief of Depressive Symptoms of Elderly Patients With Visual Impairment.), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03473431 nacompletednot on this mapstarted 2018, after this paper: background citation

A Pilot Study of a Single Infusion of Ketamine in Relief of Depressive Symptoms of Elderly Patients With Visual Impairment.

TypeinterventionalSponsorInstituto Mexicano del Seguro SocialRan2018 to 2018Enrolled90ConditionsDepression in Old Age, KetamineArmsKetamine, control
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Stopping Cognitive Decline in Patients With Late-Life Depression: A New Front in the Fight Against Dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2018
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Katarina Arandjelovicthe IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Victoria, Australia.
Harris A Eyrethe IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Victoria, Australia; Semel Institute for Neuroscience and Human Behaviour, University of California, Los Angeles, CA, USA; the Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia, Australia.
Helen LavretskySemel Institute for Neuroscience and Human Behaviour, University of California, Los Angeles, CA, USA. Electronic address: hlavretsky@mednet.ucla.edu.

Funding

Neurobiological Mechanisms of Treatment Response in Geriatric DepressionK24MH086481 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAVRETSKY, HELEN · 2010 to 2014
$906k
NIMH NIH HHS K24 MH086481
6 · The paper itself

Abstract

backgroundThere is a relative paucity of information on both empirical and subjective treatment strategies for treatment-resistant depression (TRD), especially in late life. This paper reviews the findings from two 2016 surveys conducted through the American Psychiatric Association publication the Psychiatric Times and via a member survey by the American Association for Geriatric Psychiatry (AAGP).

methodsWe present the results of the two surveys in terms of descriptive frequencies and percentages and discuss the strengths and weaknesses of various approaches to late-life TRD.

resultsThe Psychiatric Times survey received 468 responses, and the AAGP survey received 117 responses, giving an overall sample of 585 responses. The majority (76.3%) of respondents from both groups believed that a large randomized study comparing the risks and benefits of augmentation and switching strategies for TRD in patients aged 60 years and older would be helpful, and 80% of clinicians believed their practice would benefit from the findings of such a study. Of the treatment strategies that need evidence of efficacy, the most popular options were augmentation/combination strategies, particularly augmentation with aripiprazole (58.7%), bupropion (55.0%), and lithium (50.9%).

conclusionsLate-life TRD constitutes a large proportion of clinical practices, particularly of geriatric psychiatry, with lacking evidence of efficacy of most treatment strategies. These surveys indicate a clear need for a large randomized study that compares risks and benefits of augmentation and switching strategies.

Indexed as

Attitude of Health PersonnelPsychiatryAgedAntidepressive AgentsAntipsychotic AgentsAripiprazoleBupropionDepressive Disorder, Treatment-ResistantDrug Therapy, CombinationFemaleHumansLithium CompoundsMaleMiddle AgedSurveys and QuestionnairesAntidepressive AgentsAntipsychotic AgentsAripiprazoleBupropionLithium Compoundsdepressionlate-lifesurveytreatment

Identifiers

PMID27591914
PMCPMC5540329

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.